Results 81 to 90 of about 9,194,076 (301)

Anti-HIV therapy: pipeline approaches and future directions [PDF]

, 2011
Human immunodeficiency virus (HIV), with about 30 million deaths and double infections (in developing countries), is an open challenge today for global scientists.
Lavkush Dwivedi, Mansi Shrivastava
core   +1 more source

Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series

British Journal of Clinical Pharmacology, EarlyView.
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno, Berta Torres, Maria Martínez‐Rebollar, Paula Arreba, Octavi Roman, Roger LLobet, Leire Berrocal, Alberto Foncillas, Júlia Calvo, Abiu Sempere, Ivan Chivite, Elisa de Lazzari, Josep Mallolas, Ana González‐Cordón   +13 more
wiley   +1 more source

HIV pathogenesis in the female genital tract during chronic HIV infection : the impact of inflammation, T cell memory differentiation status and homeostatic cytokines on mucosal T cell immunity [PDF]

, 2010
Includes bibliographical references (leaves 124-150).The female genital tract serves as the major portal of entry for human immunodeficiency virus (HIV).
Gumbi, Pamela
core   +1 more source

Treatment as the Best Prevention: Twice-Yearly Lenacapavir, a Game Changer in Ending the AIDS Epidemic

Viruses
Despite over four decades of unremitting efforts since the discovery of acquired immunodeficiency syndrome (AIDS)/human immunodeficiency virus (HIV), there remains no cure for HIV nor a vaccine for its prevention [...]
Ziyu Wen, Minjuan Shi, Caijun Sun
doaj   +1 more source

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat [PDF]

, 2010
Background: The maturation inhibitor bevirimat (BVM) potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking capsid-spacer peptide 1 (CA-SP1) cleavage. Recent clinical trials demonstrated that a significant proportion of HIV-
Sakalian Michael, Karl Salzwedel, Salzwedel Karl, Catherine S. Adamson, Eric O. Freed, Sakalian, M, Michael Sakalian, Adamson, Catherine S, Salzwedel, K, Freed Eric O, Freed, E.O., Adamson Catherine S   +11 more
core   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Modeling HIV-1 infection in the brain.

PLoS Computational Biology, 2020
While highly active antiretroviral therapy (HAART) is successful in controlling the replication of Human Immunodeficiency Virus (HIV-1) in many patients, currently there is no cure for HIV-1, presumably due to the presence of reservoirs of the virus. One
Colin T Barker, Naveen K Vaidya
doaj   +1 more source

Quantitative Live-Cell Imaging of Human Immunodeficiency Virus (HIV-1) Assembly [PDF]

, 2012
Advances in fluorescence methodologies make it possible to investigate biological systems in unprecedented detail. Over the last few years, quantitative live-cell imaging has increasingly been used to study the dynamic interactions of viruses with cells ...
Barbara Müller, Viola Baumgärtel, Müller, Barbara, Lamb, Don C., Baumgärtel, Viola, Don C. Lamb   +5 more
core   +1 more source

Isolating T‐Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion‐Exchange Adsorbents

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Generation of CAR‐T cell therapies relies predominantly on lentiviral vectors (LVs). As in vivo CAR‐T trials progress, demand for larger quantities of higher‐potency LV is expected. However, primary capture by anion‐exchange chromatography (AIEX) remains a major manufacturing bottleneck from use of adsorbents not tailored to LVs, leading to ...
George Pamenter, Gyorgy Ovari, Anurag Kulkarni, Thomas Williams‐Fegredo, Carol Knevelman, Kyriacos Mitrophanous, Lee Davies, Farzad Foroutan, Matthew Townsend, Stephen Goldrick, Daniel G. Bracewell   +10 more
wiley   +1 more source

True story about HIV: theory of viral sequestration and reserve infection

HIV/AIDS: Research and Palliative Care, 2011
Simon Situma BarasaKenya Polytechnic University College, Nairobi, KenyaAbstract: Radical cure of infectious disease lies in the principle that the contagion is eliminated and its propagation within the body is stopped.
Barasa S
doaj